| 摘要: |
| 肝细胞癌（HCC）是最常见的恶性肿瘤之一，其发病率和死亡率近年来不断攀升。随着肿瘤免疫学的快速发展，以免疫检查点抑制剂（ICI）为主的免疫疗法为HCC的治疗带来了新的曙光。针对程序性死亡受体1等免疫检查点分子的ICI已在HCC相关治疗临床试验中显示出很好的疗效和安全性，但不同的治疗方案也存在各自的局限性。本文将介绍目前ICI在HCC治疗中的研究进展，并概述其在临床治疗中面临的挑战。 |
| 关键词: 肝细胞癌 免疫检查点抑制剂 联合治疗 辅助治疗 新辅助治疗 |
| DOI：10.16781/j.CN31-2187/R.20220521 |
| 投稿时间：2022-06-20修订日期：2022-07-17 |
| 基金项目:上海市细胞工程重点实验室项目(14DZ2272300),上海市优秀学术带头人计划(18XD1405400). |
|
| Immune checkpoint inhibitors in treatment of hepatocellular carcinoma: progress and challenge |
| WANG Zhi-jie,GAO Peng*,DING Jin* |
(Clinical Cancer Institute, Center of Translational Medicine, Naval Medical University (Second Military Medical University), Shanghai 200433, China
*Corresponding authors) |
| Abstract: |
| Hepatocellular carcinoma (HCC) is one of the most common cancers,with rising morbidity and mortality in recent years.With the rapid development of tumor immunology,immunotherapy based on immune checkpoint inhibitors (ICIs) has brought a new dawn for the treatment of HCC.ICIs targeting immune checkpoint molecules such as programmed cell death protein 1 have shown good efficacy and safety in clinical trials of HCC-related therapies.However,different treatment regimens also have their own limitations.This review introduces the current research progress of ICIs in the treatment of HCC and outlines the challenges in the clinical treatment. |
| Key words: hepatocellular carcinoma immune checkpoint inhibitors combination therapy adjuvant therapy neoadjuvant therapy |
